The objective of this Specialty Section (founded in 2007) is to promote exchange of information among academic, clinical and preclinical researchers in ocular toxicology. The Section provides a forum for the interaction of toxicologists and other professionals involved in ocular toxicity/toxicology studies. Exchange of information is promoted through annual business meetings, sponsorship of sessions/workshops for the annual meeting and liaisons with other professional organizations.

**Leadership Committee**

**President:** Brenda Birkestrand Smith, Allergan  
**Vice President:** Kathleen Krenzer, iuvo BioScience  
**VP-Elect:** Hiromi Hosako, Alcon  
**Treasurer:** Neera Tewari-Singh, Michigan State  
**Communications:** Vlad Bantseev, Genentech  
**Councilors:** Qihong Huang, Boehringer-Ingelheim  
Denise Rodeheaver, Alcon  
**Postdoctoral Representative:** Dinesh Goswami, UC Denver  
**Graduate Student Representative:** Juliana Falero-Perez, University of Wisconsin  
**Past-President:** Mercedes Salvador-Silva, Alcon

**Mission**

The objective of this Specialty Section (founded in 2007) is to promote exchange of information among academic, clinical and preclinical researchers in ocular toxicology. The Section provides a forum for the interaction of toxicologists and other professionals involved in ocular toxicity/toxicology studies. Exchange of information is promoted through annual business meetings, sponsorship of sessions/workshops for the annual meeting and liaisons with other professional organizations.

**Recent Career Achievement Awards**

- Dr. Richard Dubielzig, UW-Madison (2016)  
- Dr. Masaaki Kurata, Senju Pharmaceutical (2019)

**Goals**

- To serve as the focal point for interaction of members of the Society of Toxicology interested in Ocular Toxicology.  
- To develop, propose, and conduct programs and educational activities that emphasize the latest developments in Ocular Toxicology.  
- To relate those developments to the activities of the Society of Toxicology and to stimulate new growth in Ocular Toxicology as it relates to the science of toxicology.  
- To share information with other professional organizations related to Ocular Toxicology.  
- To act as a resource to the Society in the area of the Section’s interest.  
- To advocate the development of sound science-based guidelines for ocular assessment of therapeutics and update, as needed, guidelines for ocular irritancy assessment.  
- To organize educational programs which emphasize new developments and issues in ocular toxicology.

**Future Directions for the Assessment of Ocular Toxicology**

**Advances in technology**

Use of technologies such as next-generation imaging techniques to assess the morphology and function of the retina.

**New therapies for ocular diseases**

Increased use of biopharmaceuticals and the assessment of effects in the eye. Development of novel therapeutics such as drug/device combinations, and cell and gene therapy.

**New ocular disease models**

New models are currently being developed that mimic such diseases as Dry AMD.

**Membership (~100)**

- **Pharma/Biotech:** 48%  
- **Consulting:** 12%  
- **Academic:** 10%  
- **Government:** 6%  
- **Others:** 4%

- **Academic:** 10%